PAMREVLUMAB ( DrugBank: Pamrevlumab )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	12
113	筋ジストロフィー	13

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

diseases per page:

Showing 1 to 10 of 12 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2051210169	16/01/2022	05/02/2022	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumabin S ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumabin S ...	Idiopathic Pulmonary Fibrosis	Pamrevlumabor placebo, 30 mg/kg, IV, Day 1 and every 3 weeks thereafter, up to Week 48, for a total ...	Tracy Ganske	NULL	Recruiting	>= 40age old	<= 85age old	Both	34	Phase 3	United States;Argentina;Chile;Russia;Australia;Taiwan;Hong Kong;South Korea;the People's Republic of ...
2	EUCTR2020-000697-22-IE (EUCTR)	04/05/2021	02/12/2020	A study to compare the use of Pamrevlumabwith Placebo in patients with Idiopathic Pulmonary Fibrosis ...	Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pa ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	340	Phase 3	Serbia;Czechia;Spain;Ukraine;Ireland;Lebanon;Colombia;United Kingdom;Switzerland;Italy;France;Hungar ...
3	EUCTR2020-000697-22-PL (EUCTR)	13/04/2021	03/12/2020	A study to compare the use of Pamrevlumabwith Placebo in patients with Idiopathic Pulmonary Fibrosis ...	Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pa ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	340	Phase 3	Serbia;Spain;Ukraine;Lebanon;Ireland;Colombia;Italy;India;France;Peru;Denmark;Netherlands;Czechia;Un ...
4	EUCTR2020-000697-22-NL (EUCTR)	24/12/2020	04/06/2020	A study to compare the use of Pamrevlumabwith Placebo in patients with Idiopathic Pulmonary Fibrosis ...	Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pa ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	340	Phase 3	Serbia;Czechia;Spain;Ukraine;Ireland;Lebanon;Colombia;United Kingdom;Switzerland;Italy;France;Hungar ...
5	EUCTR2020-000697-22-DK (EUCTR)	13/10/2020	14/08/2020	A study to compare the use of Pamrevlumabwith Placebo in patients with Idiopathic Pulmonary Fibrosis ...	Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pa ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	340	Phase 3	Serbia;Czechia;Spain;Ukraine;Ireland;Lebanon;Colombia;United Kingdom;Switzerland;Italy;France;Hungar ...
6	EUCTR2020-000697-22-DE (EUCTR)	13/10/2020	05/08/2020	A study to compare the use of Pamrevlumabwith Placebo in patients with Idiopathic Pulmonary Fibrosis ...	Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pa ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	340	Phase 3	Serbia;Czechia;Spain;Ukraine;Ireland;Lebanon;Colombia;United Kingdom;Switzerland;Italy;France;Hungar ...
7	NCT04419558 (ClinicalTrials.gov)	September 30, 2020	3/6/2020	Zephyrus II: Efficacy and Safety Study of Pamrevlumabin Participants With Idiopathic Pulmonary Fibro ...	Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pa ...	Idiopathic Pulmonary Fibrosis	Drug: Pamrevlumab;Drug: Placebo	FibroGen	NULL	Recruiting	40 Years	85 Years	All	340	Phase 3	United States;Argentina;Brazil;China;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germ ...
8	EUCTR2020-000697-22-IT (EUCTR)	29/07/2020	21/01/2021	A study to compare the use of Pamrevlumabwith Placebo in patients with Idiopathic Pulmonary Fibrosis ...	Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pa ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Name: Pamrevlumab Product Code: [FG-3019] INN or Proposed INN: PAMREVLUMAB	FIBROGEN	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	340	Phase 3	Serbia;Czechia;Spain;Ukraine;Ireland;Lebanon;Colombia;United Kingdom;Italy;India;France;Hungary;Mexi ...
9	EUCTR2020-000697-22-HU (EUCTR)	08/07/2020	22/05/2020	A study to compare the use of Pamrevlumabwith Placebo in patients with Idiopathic Pulmonary Fibrosis ...	Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pa ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	340	Phase 3	Serbia;Spain;Ukraine;Lebanon;Ireland;Colombia;Italy;United Kingdom;India;France;Hungary;Czech Republ ...
10	NCT03955146 (ClinicalTrials.gov)	June 18, 2019	16/5/2019	Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumabin Participants With Idiopathic Pulmonar ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumabin S ...	Idiopathic Pulmonary Fibrosis	Drug: Pamrevlumab;Drug: Placebo	FibroGen	NULL	Active, not recruiting	40 Years	85 Years	All	356	Phase 3	United States;Argentina;Australia;Chile;China;Hong Kong;Korea, Republic of;Russian Federation;Taiwan ...

First Previous1 2Next Last

先頭へ

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

diseases per page:

Showing 1 to 10 of 13 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000699-39-NL (EUCTR)	28/06/2021	09/02/2021	Evaluation of Pamrevlumabfor the Treatment of Ambulatory Patients Affected by Duchenne Muscular Dyst ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination with Sy ...	Ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;T ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	70	Phase 3	United States;France;Canada;Spain;Belgium;Austria;Australia;Netherlands;United Kingdom;Italy
2	EUCTR2020-000699-39-AT (EUCTR)	26/04/2021	29/01/2021	Evaluation of Pamrevlumabfor the Treatment of Ambulatory Patients Affected Duchenne Muscular Dystrop ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination with Sy ...	Ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;T ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	70	Phase 3	United States;France;Canada;Spain;Belgium;Australia;Austria;Netherlands;United Kingdom;Italy
3	EUCTR2020-000699-39-IT (EUCTR)	19/04/2021	04/06/2021	Evaluation of Pamrevlumabfor the Treatment of Ambulatory Patients Affected by Duchenne Muscular Dyst ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination with Sy ...	Ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;T ...	Product Name: Pamrevlumab Product Code: [FG-3019] INN or Proposed INN: PAMREVLUMAB	FIBROGEN	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	70	Phase 3	France;United States;Czechia;Canada;Spain;Belgium;Austria;Australia;Netherlands;United Kingdom;Switz ...
4	EUCTR2020-000698-26-AT (EUCTR)	02/02/2021	17/08/2020	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination with Sy ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	96	Phase 3	United States;Czechia;Spain;Austria;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Ca ...
5	EUCTR2020-000698-26-NL (EUCTR)	20/01/2021	08/09/2020	Evaluation of Pamrevlumabfor the Treatment of Male Patients Affected by Non-ambulatory Duchenne Musc ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	90	Phase 3	United States;Czechia;Spain;Austria;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Ca ...
6	EUCTR2020-000698-26-IT (EUCTR)	28/12/2020	06/11/2020	Evaluation of Pamrevlumabfor the Treatment of Male Patients Affected by Non-ambulatory Duchenne Musc ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: [FG-3019] INN or Proposed INN: PAMREVLUMAB	FIBROGEN	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	90	Phase 3	United States;Czechia;Slovakia;Spain;Turkey;Austria;Israel;Italy;Switzerland;United Kingdom;France;C ...
7	EUCTR2020-000698-26-GB (EUCTR)	16/12/2020	14/10/2020	Evaluation of Pamrevlumabfor the Treatment of Male Patients Affected by Non-ambulatory Duchenne Musc ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	90	Phase 3	United States;Slovakia;Spain;Turkey;Austria;Israel;United Kingdom;Italy;Switzerland;France;Czech Rep ...
8	EUCTR2020-000698-26-CZ (EUCTR)	15/12/2020	19/08/2020	Evaluation of Pamrevlumabfor the Treatment of Male Patients Affected by Non-ambulatory Duchenne Musc ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	92	Phase 3	France;United States;Czechia;Czech Republic;Belgium;Spain;Austria;Netherlands;United Kingdom;Italy;S ...
9	NCT04632940 (ClinicalTrials.gov)	December 11, 2020	12/11/2020	Phase 3 Trial of Pamrevlumabor Placebo in Combination With Systemic Corticosteroids in Participants ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination With Sy ...	Duchenne Muscular Dystrophy	Drug: Pamrevlumab;Drug: Placebo;Drug: Corticosteroids	FibroGen	NULL	Active, not recruiting	6 Years	11 Years	Male	70	Phase 3	United States;Australia;Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;United Kingdom;S ...
10	NCT04371666 (ClinicalTrials.gov)	July 30, 2020	29/4/2020	Phase 3 Trial of Pamrevlumabor Placebo With Systemic Corticosteroids in Participants With Non-ambula ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab(FG-3019) or Placebo in Combination With Sy ...	Duchenne Muscular Dystrophy	Drug: Pamrevlumab;Drug: Placebo;Drug: Corticosteroids	FibroGen	NULL	Active, not recruiting	12 Years	N/A	Male	92	Phase 3	United States;Australia;Austria;Belgium;Canada;China;Czechia;France;Israel;Italy;Netherlands;Spain;S ...

First Previous1 2Next Last

先頭へ